Tetanus vaccine

BIOLOGICAL2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced CancerCancerMalignancyNeoplasmTumors

Phase 1

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

CompletedNCT02737475

Bristol-Myers SquibbAdvanced Cancer

Start: 2016-06-17End: 2020-11-02Updated: 2022-01-25

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

TerminatedNCT03251924

Bristol-Myers SquibbCancer, Malignancy, Neoplasm +1

Start: 2017-09-01End: 2021-12-20Updated: 2023-02-28

Related Papers

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Clinical Cancer Research2020-11-04105 citations

Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Cancer Research2018-07-0112 citations